Xeris Pharmaceuticals begins Phase 2 trial for glucagon in Type 1 diabetes patients
Xeris Pharmaceuticals, a specialty pharmaceutical company based in Chicago, has announced the commencement of dosing in its phase 2 clinical trial. The trial aims to ... Read More
Novo Nordisk’s Fiasp gains FDA approval for fast-acting insulin, enhancing diabetes management in US
Novo Nordisk, a leading Danish pharmaceutical company, has secured a significant regulatory milestone with the US FDA approval of its innovative fast-acting mealtime insulin aspart ... Read More